HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Guillaume Goyette Selected Research

Viral Antibodies

1/2022Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Guillaume Goyette Research Topics

Disease

11COVID-19
07/2022 - 10/2020
7Infections
02/2022 - 09/2003
2Coinfection
01/2021 - 01/2021
2Convalescence
01/2021 - 01/2021

Drug/Important Bio-Agent (IBA)

6VaccinesIBA
01/2022 - 10/2020
5Neutralizing AntibodiesIBA
01/2022 - 07/2020
3AntibodiesIBA
01/2022 - 01/2021
21- (3- (2- hydroxyl- 3- piperidin- 1- yl- propoxy)- phenoxy)- 3- piperidin- 1- ylpropan- 2- olIBA
07/2022 - 02/2022
2Glycoproteins (Glycoprotein)IBA
07/2022 - 02/2022
2Immunoglobulin G (IgG)IBA
01/2022 - 01/2021
1Pharmaceutical PreparationsIBA
07/2022
1Viral AntibodiesIBA
01/2022
1ImmunosorbentsIBA
01/2022
1EnzymesIBA
01/2022
1Messenger RNA (mRNA)IBA
01/2022
1RNA (Ribonucleic Acid)IBA
11/2021
1mRNA VaccinesIBA
01/2021
1BNT162 VaccineIBA
01/2021
1AntigensIBA
09/2003

Therapy/Procedure

2Immunotherapy
07/2022 - 02/2022
2Therapeutics
07/2022 - 02/2022
1Renal Dialysis (Hemodialysis)
01/2021